Membership
Policy 2017-04-18T13:28:42+00:00

Policy

Reviews & Comments

ABSA comments re: proposed biennial review of the Select Agent and Toxin List, released on January 19, 2016.(PDF 220KB)
a letter written by Melissa Morland, MS, MBA, RBP, CBSP, President, ABSA International, to the Centers for Disease Control and Prevention, Division of Select Agents and Toxins, 14 March, 2016

ABSA comments re: proposed biennial review of the Select Agent and Toxin List, released on January 19, 2016.(PDF 220KB)
a letter written by Melissa Morland, MS, MBA, RBP, CBSP, President, ABSA International, to the Animal and Plant Health Inspection Service, Agriculture Select Agent Services, 14 March, 2016

ABSA comments re: Federal Select Agent Program (FSAP) Policy Statement entitled, “Inactivated Bacillus anthracis”, released on November 30, 2015.(PDF 220KB)
a letter written by Melissa Morland, MS, MBA, RBP, CBSP, President, ABSA International, to the Centers for Disease Control and Prevention, Division of Select Agents and to the Toxins and Animal and Plant Health Inspection Service, Agriculture Select Agent Services, 11 February, 2016

ABSA comments re: Proposed Action Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), Document number 2015-26388, 80 CFR 62543.(PDF 171KB)
a letter written by Melissa Morland, MS, MBA, RBP, CBSP, President, ABSA International, to the Office of Science Policy, National Institutes of Health, 30 November, 2015

ABSA Response to October 29, 2015 White House Biosafety Memo(PDF 231KB)

ABSA comments re: Coordinated Framework for the Regulation of Biotechnology(PDF 448KB)
a letter written by Melissa Morland, MS, MBA, RBP, CBSP, SM (NRCM), President, ABSA International, to members of the National Science and Technology Council, Emerging Technologies Interagency Policy Coordination Committee, Office of Science and Technology Policy 12 November, 2015

RE: Office of Science and Technology Policy request for comments regarding impact of the Select Agent Regulations (PDF 86KB)
a letter written by Marian Downing, RBP, CBSP, President, ABSA, to Gerald Epstein, PhD Co-Chair, Fast Track Action Committee, Deputy Assistant Secretary for Chemical, Biological, Radiological, and Nuclear Policy, U.S. Department of Homeland Security 10 April, 2015

ABSA Position Paper regarding the July 16, 2014 CDC Hearing and GAO Report High Containment Laboratories: Recent Incidents of Biosafety Lapses (PDF 423KB)
written by the ABSA Unified Oversight Task Force, 25 March, 2015

ABSA Final Comments on the Drafted Table of Contents of the Agriculture Biosafety/Biocontainment Manual (AgBMBL) – a companion to the NIH/CDC publication, “Biosafety in Microbiological and Biomedical Laboratories” (PDF 256KB)
a letter written to the USDA Animal and Plant Health Inspection Service by Marian M. Downing, RBP, CBSP, President, ABSA, 9 February, 2015

America Biological Safety Association (ABSA) Position Paper on Ebola (PDF 27KB)
12 December, 2014

White House memorandum: Enhancing Biosafety and Biosecurity in the United States(PDF 353KB)
a memorandum written by Lisa O. Monaco, Assistant to the President for Homeland Security and Counterterrorism, and John P. Holdren, Assistant toe the President for Science and Technology, 19 Aug, 2014

Re: CDC Anthrax Lab Incident Hearing and Subsequent GAO Report High Containment Laboratories: Recent Incidents of Biosafety Lapses(PDF 1.16MB)
a letter written by the ABSA Legislative Committee to the US Energy and Commerce Committee, Oversight Investigations, 31 July, 2014

Press Release: ABSA International (ABSA) Response to Recent Events at the Centers for Disease Control and Prevention (CDC)(PDF 225KB), 16 July, 2014

To the Editors of Newsweek regarding the March 13, 2014 article, “The Cure May Kill You: The Only Thing Scarier than Bio-Warfare Is the Antidote.”(PDF 196KB)
a letter written by Paul J. Meechan, PhD, RBP, CBSP, President, ABSA, 2 April, 2014

CLSI Guideline M29-A4 (Draft 2) Protection of Laboratory Workers From Occupationally Acquired Infections; Draft Guideline — Fourth Edition(PDF 649KB)
a letter written by Barbara Fox Nellis, SM(NRCM), RBP, CBSP, President, ABSA, 22 August, 2013

ABSA Request for Comments on proposal to revise the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules – Streamlining Review of Certain Human Gene Transfer Trials that Pose a Low Biosafety Risk (PDF 72KB)
a letter written by Barbara Fox Nellis, SM(NRCM), RBP, CBSP, President, ABSA, 12 June, 2013

ABSA Comments on the Federal Register Docket CDC-2012-0010: Influenza Viruses Containing the Hemagglutinin from the Goose/Guangdong/1/96 Lineage (PDF 236KB)
a letter written by Barbara Fox Nellis, RBP, CBSP, President, ABSA, 14 December, 2012

ABSA Comments on the draft National Action Plan to Prevent Health-care Infections announced in the April 25th, 2012 Federal Register. (PDF 264KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA, 7 June, 2012

ABSA Comments on the October 3, 2011 Federal Register announcement regarding the proposed revisions to the Foreign Quarantine; Etiological Agents, Hosts, and Vectors standard announced in the Federal Register on October 14, 2011. (PDF 560KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA, 12 December, 2011

ABSA Comments on the October 3, 2011 Federal Register announcement regarding the proposed revisions to the Possession, Use, and Transfer, of Select Agents and Toxins standard. (PDF 176KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA, 30 November, 2011

Federal Experts Security Advisory Panel Meeting(PDF 307KB)
a presentation by Michelle McKinney, MS, CBSP ABSA Councilor, July 21, 2011

ABSA Comments on the proposed revisions to the “NIH Guidelines for Research with Recombinant DNA (NIH Guidelines)” which were announced in the Federal Register on July 25, 2011. (PDF 140KB)
a letter written by Karen Byers, MS, RBP, CBSP, President, ABSA, 6 September, 2011

ABSA Domestic and Global Biosafety Training Support Letter(PDF 75KB)
a letter to the US Congress written by Karen Byers, MS, RBP, CBSP, President ABSA

ABSA comments on final draft of the CWA WS53 Biosafety Professional Competencies(PDF 44KB)

ABSA Comments on the July 21, 2010 Federal Register announcement regarding the biennial review and republication of the Department of Health and Human Services (DHHS) list of select agents and toxins. (PDF 140KB)
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 30 August, 2010

ABSA Comments on the proposed exemption of well-characterized transgenic animals from the NIH Guidelines.
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 10 August, 2010

ABSA Comments on the NIH Guidelines for Research with Recombinant DNA
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 31 May, 2010

ABSA Comments on the Screening Framework Guidance for Synthetic Double Stranded DNA Providers
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 21 January, 2010

Legislative Issues


ABSA Request for Comments on proposal to revise the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules – Streamlining Review of Certain Human Gene Transfer Trials that Pose a Low Biosafety Risk (PDF 72KB)
a letter written by Barbara Fox Nellis, SM(NRCM), RBP, CBSP, President, ABSA, 12 June, 2013


 

ABSA Domestic and Global Biosafety Training Support Letter(PDF 75KB)
a letter to the US Congress written by Karen Byers, MS, RBP, CBSP, President ABSA

Open Letter from the ABSA Legislative Committee(PDF 100KB); July 22, 2009

Select Agent

S.485(PDF 180KB) To reauthorize the Select Agent Program by amending the Public Health Service Act and the Agricultural Bioterrorism Protection Act of 2002 and to improve oversight of high containment laboratories.

H. R. 1225(PDF 180KB) To reauthorize the Select Agent Program by amending the Public Health Service Act and the Agricultural Bioterrorism Protection Act of 2002 and to improve oversight of high containment laboratories.

Center for Biosecurity of the University of Pittsburgh Medical Center (UPMC) letter of support for H.R. 6671, The Select Agent Program and Biosafety Improvement Act of 2008(PDF 80KB)

The National Science Advisory Board for Biosecurity (NSABB) report on Enhancing Personnel Reliability Among Individuals with Access to Select Agents(PDF 364KB)

WMD

The World at Risk: The Report of the Commission on the Prevention of WMD Proliferation and Terrorism(PDF 2MB)

August 11, 2009 – WMD Prevention and Preparedness Act(PDF 193KB)
     Section by Section Description(MS Word 45KB)
     One Page Description(MS Word 40KB)

BioSecurity

Report of the Trans-Federal Task Force on Optimizing Biosafety and Biocontainment Oversight(PDF 1.14MB)

GAO – HIGH-CONTAINMENT LABORATORIES: National Strategy for Oversight Is Needed(PDF 2.1MB)

Executive Order 13486(PDF 44KB) of January 9, 2009 Strengthening Laboratory Biosecurity in the United States

Oversight of High-Containment Biological Laboratories: Issues for Congress(PDF 356KB)

Biological Safety Training Programs as a Component of Personnel Reliability (PDF 300KB)